Search Results for “medical device” – Page 71 – media

Philips launches stent system to restore blood flow in blocked veins

Dive Brief Philips has launched its Duo Venous Stent System in the U.S. to treat patients with blockages in their veins, the company said Wednesday. The implant, which won approval in December, is designed to address the root cause of chronic deep venous disease and comes in two forms for use in different types of veins. Philips acquired the device in its 2022 takeover of Vesper Medical. The company paid 227 million euros upfront for Vesper to expand its image guided therapy business. Dive Insight The Duo Venous Stent System is a portfolio of self-expanding stents mounted on disposable delivery devices. Vesper designed the stents to increase the diameter of obstructed veins. Restoring blood flow could improve quality of life by alleviating symptoms of venous disease, which include pain, swelling and discoloration of skin. Philips tracked improvements on observational quality-of-life endpoints in a trial of the device. Using data from ...
- Source: drugdu
- 128
- June 17, 2024
Tianjin establishes health care group to create a new model for health care industry

The reporter learned from the Tianjin State-owned Assets Supervision and Administration Commission that Tianjin Health and Elderly Care Group Co., Ltd. (hereinafter referred to as Health and Elderly Care Group), a Class II commercial enterprise directly supervised by the commission, was recently established and put into operation. It is promoting the high-quality and coordinated development of the health and elderly care industry by exploring the parallel path of providing market-oriented mid- to high-end health and elderly care services and inclusive elderly care services supported by government policies. According to reports, Kangyang Group is positioned as the main body of investment, operation and implementation of Tianjin’s health and elderly care industry, with the integration of medical care and elderly care as its core, based on “health, medical care, health, elderly care and integration”, covering home, community, institutions and other fields, and will serve the Beijing-Tianjin-Hebei region through market-oriented methods, facing the ...
- Source: drugdu
- 105
- June 1, 2024
Lipoprotein Blood Test Detects Hereditary Cardiovascular Risk

Lipoprotein (a), or Lp(a), is increasingly recognized as a critical but under-acknowledged potential risk factor for cardiovascular diseases, which are a significant public health concern. Around 20% of the global population has high levels of Lp(a), which heightens their risk of conditions such as myocardial infarction and stroke. Elevated Lp(a) levels contribute to the accumulation of lipids within artery walls, facilitating plaque formation and heightening the risk of cardiovascular events. While factors such as menopause, and kidney or liver diseases, as well as hyperthyroidism can affect Lp(a) levels, over 90% of the variability in Lp(a) levels is due to genetic differences in the lipoprotein (a) (LPA) gene. Consequently, testing for Lp(a) is a crucial diagnostic tool that helps clinicians accurately evaluate cardiovascular risk, and its integration into routine diagnostics is anticipated soon. Roche’s (Basel, Switzerland) Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and ...
- Source: drugdu
- 106
- May 28, 2024
Lipoprotein Blood Test Detects Hereditary Cardiovascular Risk

Lipoprotein (a), or Lp(a), is increasingly recognized as a critical but under-acknowledged potential risk factor for cardiovascular diseases, which are a significant public health concern. Around 20% of the global population has high levels of Lp(a), which heightens their risk of conditions such as myocardial infarction and stroke. Elevated Lp(a) levels contribute to the accumulation of lipids within artery walls, facilitating plaque formation and heightening the risk of cardiovascular events. While factors such as menopause, and kidney or liver diseases, as well as hyperthyroidism can affect Lp(a) levels, over 90% of the variability in Lp(a) levels is due to genetic differences in the lipoprotein (a) (LPA) gene. Consequently, testing for Lp(a) is a crucial diagnostic tool that helps clinicians accurately evaluate cardiovascular risk, and its integration into routine diagnostics is anticipated soon. Roche’s (Basel, Switzerland) Tina-quant lipoprotein Lp(a) RxDx assay has received Breakthrough Device Designation from the U.S. Food and ...
- Source: drugdu
- 123
- May 27, 2024
Pharmed Vietnam 2024

Organiser：Adpex JSC Time：11- 14 September 2024 address：Lawrence S. Ting Building 801 Nguyen Van Linh Parkway, Dist. 7 Ho Chi Minh City Vietnam Exhibition hall：Saigon Exhibition & Convention Center Product range: Medical Products Exhibition area: Medical equipment and instruments, medical consumables, medical dressings, surgical equipment, rescue equipment, diagnostic equipment and supplies, ophthalmic instruments and equipment, ENT equipment, dental equipment and supplies, medical reagents and equipment, medical health products and equipment, medical institutions and laboratory technology equipment, medical information and technology exchange, beauty equipment Analytical Instruments Exhibition area: Optical analysis instruments, mass spectrometers, spectrometers, chromatographs, spectrometers, electrochemical analysis instruments, X-ray analysis instruments, gas chromatography, liquid chromatography, thermal analysis instruments, all kinds of portable instruments, surface analysis instruments, nuclear analysis instruments, elemental analysis instruments, process analysis instruments, composition analysis instruments, injection analysis instruments and other general analytical instruments Laboratory Equipment Exhibition area: Laboratory instruments and equipment, laboratory automation and accessories, optical instruments and equipment, ...
- Source: drugdu
- 167
- May 27, 2024
Innovative Fundus Disease Drug Busilixumab Completes First Injections in Mainland Public Hospitals, Benefiting More Fundus Disease Patients

Recently, Guangdong Provincial People’s Hospital successfully completed the injection of the innovative drug Busiliximab, which is also the first batch of injection of this drug in public hospitals in mainland China. Relying on the “Hong Kong-Macau Pharmaceutical and Device Access” policy, Busiliximab has been approved for urgent clinical use in designated medical institutions in the Greater Bay Area. This new generation of anti-VEGF (vascular endothelial growth factor) drugs in public hospitals will enhance the accessibility of innovative therapies and benefit more patients with fundus diseases. China has more than 40 million patients with endophthalmic disease, and is in urgent need of new drugs to break through the treatment dilemma. The number of patients with fundus diseases in China is increasing, with the potential number of patients with fundus diseases reaching 40 million. The most common of them are diabetic retinopathy and age-related macular degeneration, in addition to many other types ...
- Source: drugdu
- 139
- May 25, 2024
MedtecLIVE 2024

Organiser：Informa Time:18- 20 June 2024 address：Messepiazza 1, 70629 Stuttgart, Stuttgart Germany Exhibition hall: Messe Stuttgart Product range: Precision instruments: Specialized medical alloys, microprocessors, computer numerical control (CNC), ultrasound and laser technology, surgical equipment, interventional cardiac devices and medical accessories for surgical technology Medical plastics technology: medical classification of plastic raw materials, outsourcing and processing of medical consumables, packaging and drug delivery Automation equipment technology: automatic production process about automatic setting, assembly process and robot motion control Pharmaceutical packaging: Packaging solutions from filling processes to packaging materials and from disposable product manufacturers to outsourcers About MedtecLIVE： The German medical equipment and medical technology exhibition MedtecLIVE, the second largest exhibition in Europe’s medical technology field, is held once a year, covering the entire supply chain, and more than 400 medical suppliers from the global medical technology field present innovative products, solutions and services for distributors and equipment manufacturers. Discuss the most important ...
- Source: drugdu
- 196
- May 23, 2024
J&J expands dermatology portfolio with $850m Proteologix acquisition

In a bid to solidify its footing in dermatology, Johnson & Johnson (J&J) has announced that it will purchase the immune-mediated disease-focused biotech Proteologix in a $850m cash buyout, with the potential for additional milestone payments. The host of bispecific antibodies brought by Proteologix to the deal will add depth to J&J’s immunology pipeline, and more specifically, bolster its position to address atopic dermatitis (AD). Among Proteologix’s assets is PX128, a bispecific antibody designed to target interleukin (IL)-13, as well as the cytokine TSLP, which is being developed for the treatment of patients with moderate to severe AD and moderate to severe asthma. The acquisition also covers the preclinical stage candidate, PX130, a bispecific antibody designed to target both IL-13 and IL-22 to inhibit inflammation, restore the skin barrier, and prevent environmental trigger-mediated inflammation of the skin. The asset is under development for the treatment of moderate to severe AD. ...
- Source: drugdu
- 85
- May 21, 2024
Securing Audience Measurement in Pharma Marketing

Ray Kingman The industry must find a way to balance consumer privacy and a return on investment in pharma marketing. Promoting advances in pharmaceuticals is full of challenges. From recruiting clinical trial participants, to engaging patients with their permission at the point of care, to creating brand lift and awareness, the marketing landscape for pharma presents both logistical and regulatory obstacles when it comes to constructing and executing a successful marketing program. Identity, and how it is managed, presents special challenges for audience targeting and especially measurement of campaign performance in an evolving identity resolution environment. Across our multi-channel, multi-platform and multi-media landscape the signals that avail us for targeting and measurement are often impeded by the requirement to block or exercise restraint when it comes to sensitive data and patient privacy rights. Building privacy-compliant audiences for pharma campaigns takes special care, but identifying audience engagement that measures campaign outcomes ...
- Source: drugdu
- 88
- May 10, 2024
Amgen Puts Its Weight Behind Obesity Drug With Potential Edge Over Lilly, Novo Nordisk Meds

Amgen is confident its injectable obesity drug would have a differentiated profile compared to medications now on the market from Novo Nordisk and Eli Lilly and it’s now preparing for Phase 3 testing. But an oral obesity drug in Amgen’s pipeline will not advance beyond Phase 1. By Frank Vinluan Amgen aims to challenge the Novo Nordisk and Eli Lilly duopoly in the market for injectable obesity medications, and the company is now preparing for Phase 3 testing of an injectable drug candidate that would introduce new competition. While executives are not yet sharing specific details of the clinical data that support these plans, Amgen’s drug candidate could have dosing and manufacturing advantages. The update for the drug, maridebart cafraglutide or MariTide (known in earlier stages of development as AMG 133), came with Amgen’s report of financial results for the first quarter of 2024. CEO Robert Bradway said the company ...
- Source: drugdu
- 113
- May 6, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.